SOURCE-LINKED STUDY SUMMARY
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
What was studied?
This single-centre, masked, randomized phase 1b/2a trial assessed injected amycretin versus placebo. Adverse events were primary; weight change was secondary.
What changed?
At 36 weeks, estimated weight loss was 24.3% with 60 mg versus 1.1% with placebo. Gastrointestinal events were most common, generally mild to moderate, and resolved by study end.
Who was studied?
125 adults with overweight or obesity were randomized: 101 to amycretin and 24 to placebo. Eligibility required ages 18–55.
Studied exposure
Weekly subcutaneous treatment escalated from 0.3 mg to 60 mg over 36 weeks, or to maintenance doses of 20 mg (36 weeks), 5 mg (28 weeks), or 1.25 mg (20 weeks).
What remains uncertain?
Many participants withdrew, often for reasons unrelated to treatment-emergent adverse events, limiting interpretation of the results.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(25)01185-7